Investor Briefcase   
Investor Kit   
Glossary   
News Feeds    
Print page    Print
E-mail page    E-mail





 


GLOSSARY (0-9)

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

0 - 9

1%/10 net 30
A way of providing cash discounts on purchases. It means that if the bill is paid within 10 days, there is a 1% discount. Otherwise, the total amount is due within 30 days. For example, if "$1000 1/10 net 30" is written on a bill, the buyer can take a 1% discount ($1000 x .01 = $10) and make a payment of $990 within 10 days, or pay the entire $1000 within 30 days.
10-K
An annual report required by the SEC each year that is a comprehensive summary of a company's performance. Typically the 10-K contains much more detail than the annual report. It includes information such as company history, organizational structure, equity, holdings, earnings per share, subsidiaries, etc.
10-Q
A quarterly report submitted by all public companies to the SEC in which firms are required to disclose relevant information regarding their financial position. This must be done on time, and the information should be available to all interested parties.
10-year Treasury Note
A debt obligation issued by the U.S. Treasury that has a term of more than one year, but not more than 10 years.
1040 Form
The standard IRS form that individuals use to file their annual income tax return.
1040A Form
A simplified version of the 1040 form for individual income tax. To be eligible to use a 1040A form, an individual must not itemize or own a business and their taxable income has to be under $50,000.
1040EZ Form
Similar to the 1040 income tax form, 1040EZ offers a faster and easier way to file your taxes. This form is only eligible for people with income less than $50,000 and interest income of $400 or less.
1040PC Form
An income tax return that is prepared by computer in a three column "answer-sheet" format. It only prints the bottom line number, dollar amount, and, for most entries, a brief description called a "legend page."
12B-1 Fees
A provision that allows a mutual fund to collect a small fee from investors. This fee is designated for promotions, sales, or any other activity connected with the distribution of the fund's shares. The fee must be reasonable: 0.5% to 1% of the fund's net assets, and up to a maximum of 8.5% of the offering price per share.
12B-1 Plan
A no-load mutual fund that is allowed to use fund assets to pay for distribution costs rather than charging a 12b-1 fee. The 12b-1 fee is an annual percentage charge based on the current value of the investment.
30 Year Treasury
A U.S. Treasury debt obligation that has a maturity of 30 years. The 30-year Treasury used to be the benchmark U.S. bond and one of the world's most widely watched financial instruments.
3C1
A portion of the Investment Company Act of 1940 that permits the exclusion of investment companies from standard registration requirements with the SEC if they have fewer than 100 U.S. investors.
3C7
A portion of the Investment Company Act of 1940 that permits the exclusion of investment companies from standard registration requirements with the SEC if all U.S. investors are considered to be "qualified purchasers" or "accredited investors."
401(k) Plan
A qualified plan established by employers to which eligible employees may make salary deferral (salary reduction) contributions on a post and/or pre-tax basis. Employers may make matching or non-elective contributions to the plan on behalf of eligible employees and may also add a profit sharing feature to the plan. Earnings accrue on a tax-deferred basis.
403(b) Plan
A 403(b) plan, also known as a tax-sheltered annuity (TSA) plan, is a retirement plan for certain employees of public schools, employees of certain tax-exempt organizations and certain ministers. Individual accounts in a 403(b) plan can be any of the following types:- An annuity contract, which is provided through an insurance company,- A custodial account, which is invested in mutual funds or- A retirement income account set up for church employees.Generally, retirement income accounts can invest in either annuities or mutual funds.
457 Plan
A non-qualified, deferred compensation plan established by state and local governments and tax-exempt governments and tax-exempt employers. Eligible employees are allowed to make salary deferral contributions to the 457 plan. Earnings grow on a tax-deferred basis and contributions are not taxed until the assets are distributed from the plan.
52 Week High/Low
The highest and lowest prices at which a stock was sold in the past year (52 weeks).
529 Plan
A plan that allows for the prepayment of qualified higher education expenses at eligible educational institutions. Also known as a "qualified tuition program."
8-K
A report of unscheduled material events or corporate changes at a company that could be of importance to the shareholders or the SEC.
90-Day Letter
An IRS notice sent after an audit stating that there was a discrepancy or error within an individuals taxes and they will be assessed unless petitioned.

Back to top

Portions of this page copyright © Investopedia.com

 

Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

     
CONTACT US    |    PRIVACY    |    TERMS OF USE
Copyright © 2008 Savient Pharmaceuticals, Inc. All rights reserved.